CLSD
Clearside Biomedical, Inc.
Set alert
0.41 USD 0.00 0.00%
Day range unavailable
52-week range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- —
- Prev close
- 0.41
- Mkt cap
- 66.72M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.76
- Beta
- 2.33
- Short ratio
- 1.21
- Inst. own
- 23.17%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.07
- 200-d avg
- 1.22
- 1y target
- 6.00
Key statistics
- Market cap
- 66.72M
- Enterprise value
- 98.96M
- Trailing P/E
- 0.00
- Forward P/E
- -1.76
- PEG ratio
- 0.00
- Price / sales
- 8.87
- Price / book
- 0.00
- EPS (TTM)
- -0.45
- Beta
- 2.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.52M
- Revenue growth
- -91.20%
- Free cash flow
- -17.50M
- Total cash
- 29.36M
- Total debt
- 47.59M
- Return on equity
- 0.00%
- Shares outstanding
- 75.84M
- Short % of float
- 2.50%
- 50-day average
- 1.07
- 200-day average
- 1.22
Analyst view
Consensus: none
Price target (mean) 6.00 +1363.4% upside
Now 0.41
- Target (low)
- 5.00
- Target (mean)
- 6.00
- Target (high)
- 8.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.098.
Financials — quick view
CLSD Revenue — quarterly 0
CLSD Net income — quarterly -5.97M
CLSD EPS — quarterly -1.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.14 | -0.10 | +0.04 | +28.57% |
| Aug 12, 2024 | Jun 1, 2024 | -0.14 | -0.10 | +0.04 | +28.57% |
| May 9, 2024 | Mar 1, 2024 | -0.14 | -0.17 | -0.03 | -21.43% |
| Mar 12, 2024 | Dec 1, 2023 | -0.10 | -0.08 | +0.02 | +20.00% |
| Nov 13, 2023 | Sep 1, 2023 | -0.16 | -0.15 | +0.01 | +6.25% |
| Aug 14, 2023 | Jun 1, 2023 | -0.14 | -0.15 | -0.01 | -7.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2024 | Needham | reit | Buy | Buy |
| Oct 14, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 10, 2024 | Needham | main | Buy | Buy |
| Aug 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- clearsidebio.com
News
- Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
- Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on CLSD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHONG NGAI HANG VICTOR | Officer | Purchase | Oct 31, 2024 | 100,000 |
| CIULLA THOMAS A. | Officer | Sale | Jan 19, 2023 | 291,890 |
| DEIGNAN CHARLES A | Chief Financial Officer | Sale | Jan 18, 2024 | 384,662 |
| GIBNEY ANTHONY S. | Director | Purchase | Apr 17, 2024 | 100,000 |
| HUMPHRIES WILLIAM DOUGLAS | Director | Conversion of Exercise of derivative security | Sep 21, 2023 | 51,040 |
| HUTSON NANCY J | Director | Purchase | Oct 2, 2023 | 93,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.74% | 2,839,978 | 2.50M | Sep 29, 2024 |
| Carmignac Gestion | 2.55% | 1,933,531 | 1.70M | Sep 29, 2024 |
| Blackrock Inc. | 1.06% | 803,955 | 707.24K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.98% | 744,889 | 655.28K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.96% | 731,386 | 643.40K | Sep 29, 2024 |
| First Manhattan Co. LLC | 0.88% | 666,142 | 586.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.60% | 1,970,683 | 1.73M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.03% | 783,853 | 689.55K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.51% | 390,578 | 343.59K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.34% | 255,000 | 224.32K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.21% | 162,855 | 143.26K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 140,267 | 123.39K | Oct 30, 2024 |